Filtered By:
Drug: Herceptin
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
This study evaluated the activity and safety of a combination of dendritic cell (DC) vaccination given with mAb and cytotoxic therapy. We performed a phase I/II study using autologous DCs pulsed with two different HER2 peptides given with trastuzumab and vinorelbine to a study cohort of patients with HER2-overexpressing and a second with HER2 nonoverexpressing metastatic breast cancer. Seventeen patients with HER2-overexpressing and seven with nonoverexpressing disease were treated. Treatment was well tolerated, with one patient removed from therapy because of toxicity and no deaths. Forty-six percent of patients had stabl...
Source: Journal of Immunology - May 19, 2023 Category: Allergy & Immunology Authors: Benjamin G Vincent Danielle M File Karen P McKinnon Dominic T Moore Jeffrey A Frelinger Edward J Collins Joseph G Ibrahim Lisa Bixby Shannon Reisdorf Sonia J Laurie Yara A Park Carey K Anders Frances A Collichio Hyman B Muss Lisa A Carey Hendrik W van Dev Source Type: research
HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment
CONCLUSION: HER2/neu-based peptide vaccine is a safe and effective approach against breast cancer, and its benefits can be potentially furthered by combining the li-Key hybrid vaccine with targeted drugs and adjuvants selected to enhance cross-presentation for exogenous vaccine antigens. Graphical abstract was created with Biorender.com (license number: HA24UHRBV4 and FP24UHRGDD).PMID:36692548 | DOI:10.1007/s00432-023-04574-9
Source: Clinical Genitourinary Cancer - January 24, 2023 Category: Cancer & Oncology Authors: Yihan Zhou Source Type: research
Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer
CONCLUSIONS: Our findings suggested that IP-10-(anti-HER2 scFv) fusion protein can specifically direct IP-10 to the HER2-expressing tumor cells and may act as an adjuvant along with HER2-based vaccine to gather the elicited immune response at the site of HER2-overexpressimg tumors.PMID:36650341 | DOI:10.1007/s10529-022-03342-y
Source: Biotechnology Letters - January 17, 2023 Category: Biotechnology Authors: Maryam Ahmadzadeh Elham Mohit Source Type: research
Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
Transl Oncol. 2022 Mar 5;19:101378. doi: 10.1016/j.tranon.2022.101378. Online ahead of print.ABSTRACTIn pre-clinical and clinical settings, active immunization with a Her-2/neu vaccine (HerVaxx), comprising B-cell peptide from Trastuzumab binding site, has been shown to reduce primary tumor growth via induction of polyclonal anti-tumor immune responses and immunological memory. Here, we tested the combination of HerVaxx and the recently identified B-cell epitope/mimotope of Pertuzumab, i.e. a multi-peptide B-cell vaccine, for preventing Her-2/neu lung metastases formation in a mouse model. Active immunization with the mult...
Source: Translational Oncology - March 8, 2022 Category: Cancer & Oncology Authors: Joshua Tobias Mirjana Drini ć Sandra H ögler Katharina Ambroz Karin Baier Petra Kodajova Erwin Tomasich Anna S Berghoff Anna Schmid Erika Garner-Spitzer Lukas Kenner Michael Kundi Christoph C Zielinski Ursula Wiedermann Source Type: research
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Transl Oncol. 2021 Aug 19;14(11):101205. doi: 10.1016/j.tranon.2021.101205. Online ahead of print.ABSTRACTEpidermal Growth Factor Receptor (EGFR) is overexpressed on a number of human cancers, and often is indicative of a poor outcome. Treatment of EGFR/HER2 overexpressing cancers includes monoclonal antibody therapy (cetuximab/trastuzumab) either alone or in conjunction with other standard cancer therapies. While monoclonal antibody therapy has been proven to be efficacious in the treatment of EGFR/HER2 overexpressing tumors, drawbacks include the lack of long-lasting immunity and acquired resistance to monoclonal therapy...
Source: Translational Oncology - August 22, 2021 Category: Cancer & Oncology Authors: Hester A Doyle Renelle J Gee Tyler D Masters Christian R Gee Carmen J Booth Elizabeth Peterson-Roth Raymond A Koski Stuart C Helfand Lauren Price Deborah Bascombe Dorothy Jackson Rita Ho Gerald R Post Mark J Mamula Source Type: research
Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options
Endocr Metab Immune Disord Drug Targets. 2021 Apr 26. doi: 10.2174/1871530321666210426125904. Online ahead of print.ABSTRACTBreast cancer (BC) stands at the first position among all forms of malignancies found in women globally. The available therapeutic approaches for breast cancer includes chemotherapy, radiation therapy, hormonal therapy and finally surgery. Despite the conventional therapies, in recent years the advance immunology based therapeutics emerge a potential in breast cancer treatment, including immune checkpoint blockades, vaccines and in combination with other treatment strategies. Although, commonly used t...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - April 27, 2021 Category: Endocrinology Authors: Kavita Singh Dhananjay Yadav Meenu Jain Pramod Kumar Singh Jun-O Jin Source Type: research
